Deutsche Bank AG trimmed its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 25.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 54,007 shares of the company’s stock after selling 18,435 shares during the period. Deutsche Bank AG owned 0.08% of Kymera Therapeutics worth $1,478,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in Kymera Therapeutics by 3.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock worth $276,395,000 after purchasing an additional 224,859 shares during the period. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock worth $143,183,000 after buying an additional 344,080 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in shares of Kymera Therapeutics by 4.6% during the 4th quarter. Driehaus Capital Management LLC now owns 1,390,372 shares of the company’s stock worth $55,935,000 after buying an additional 61,669 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth $23,856,000. Finally, Woodline Partners LP grew its stake in Kymera Therapeutics by 2.3% in the 4th quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock valued at $21,621,000 after buying an additional 12,334 shares during the last quarter.
Kymera Therapeutics Trading Up 3.5%
Shares of NASDAQ:KYMR opened at $44.10 on Friday. The firm has a market capitalization of $3.15 billion, a PE ratio of -12.71 and a beta of 2.18. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $53.27. The business’s 50 day moving average is $44.17 and its 200-day moving average is $36.62.
Analyst Ratings Changes
KYMR has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $60.00 target price (up previously from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a “buy” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 3rd. Morgan Stanley assumed coverage on Kymera Therapeutics in a research note on Thursday, July 3rd. They set an “overweight” rating and a $70.00 target price for the company. Finally, Wall Street Zen downgraded Kymera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $59.11.
Read Our Latest Stock Report on KYMR
Insider Buying and Selling at Kymera Therapeutics
In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bros. Advisors Lp Baker acquired 655,500 shares of the firm’s stock in a transaction on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the completion of the acquisition, the director directly owned 6,117,295 shares of the company’s stock, valued at approximately $269,160,980. This represents a 12.00% increase in their position. The disclosure for this purchase can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 in the last 90 days. 16.01% of the stock is currently owned by insiders.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More
- Five stocks we like better than Kymera Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Royal Caribbean Earnings Beat Fuels Strong 2025 Outlook
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Alphabet’s Breakout Potential: From Laggard to AI Leader
- What Are Growth Stocks and Investing in Them
- TJX Stock Price Hits Fresh High, Signals More Highs to Follow
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.